- Trial phase
- Approved
- Time to market
- Already approved and marketed since November 2015.
- Why 3/10
- NINLARO is an already-approved, marketed drug with no pending PDUFA, no new pivotal readout, and no scheduled label-expansion catalyst in the next 12 months. At ~$19.66, Takeda is a ~¥4.5 trillion revenue company where NINLARO is one of many products; the drug is too small a piece of the portfolio to drive a significant share-price move on its own. Per the rubric, an approved drug without a pending binary catalyst scores 3-5, and given its modest contribution to Takeda's overall business, the score lands at 3.
No hard, dated catalyst exists for NINLARO over the next 12 months. Watch for any Takeda disclosure of NINLARO-specific sales trends in quarterly earnings (next expected around late January 2027 for Q3 FY2026) and for potential label changes or post-marketing study requirements stemming from the critical meta-analyses. NINLARO's commercial trajectory as a mature product will be gradual, not binary; near-term share moves for TAK will be driven by broader portfolio events (ENTYVIO, TAKHZYRO, new launches) rather than this one drug.
Price Chart
Executive Summary
NINLARO (ixazomib) is Takeda's first-in-class oral proteasome inhibitor approved by the FDA in November 2015 for relapsed/refractory multiple myeloma. It remains a marketed product generating steady revenue, but recent academic scrutiny has undermined its clinical standing: a 2025 systematic review and meta-analysis presented at the ASH annual meeting concluded the drug has failed primary endpoints in multiple trials and produced worse overall survival in the maintenance setting (TOURMALINE-MM3 and MM4). Final OS analyses from those trials, published in 2025, found no statistically significant survival benefit over placebo. For a non-medical investor, NINLARO is a mature asset in Takeda's large, diversified portfolio and not a standalone value driver. It faces growing competition from injectable proteasome inhibitors (bortezomib, carfilzomib) and newer CAR-T therapies. There is no pending FDA decision or pivotal readout for NINLARO in the near term.
How It Works
NINLARO is a once-weekly oral pill that blocks proteasomes, which are cellular machinery that cancer cells rely on to break down old or damaged proteins. By clogging this system, the drug causes a toxic buildup of proteins inside multiple myeloma cells, killing them. It was the first oral (non-injectable) proteasome inhibitor, offering patients a convenient at-home option compared to injected alternatives like bortezomib or carfilzomib.
Trial Status
NINLARO was approved by the FDA in November 2015 based on the Phase 3 TOURMALINE-MM1 trial. Two additional Phase 3 maintenance trials (TOURMALINE-MM3 and MM4) met their primary progression-free survival endpoints, but final overall survival analyses published in 2025 showed no statistically significant benefit over placebo. A 2025 systematic review and meta-analysis presented at ASH found ixazomib failed primary endpoints in multiple trials and was associated with worse survival in the maintenance setting.
The Two-Sided Case
Upcoming Catalysts
- No upcoming FDA decision or pivotal readout identified for NINLARO in the next 12 months.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
TAKEDA PHARMACEUTICAL CO LTD 6-K TAK ·Originating report